Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 3/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.35 |
| ▸ | NPBWR1 | P48145 | 2/20 | 0.35 |
| ▸ | CNR1 | P21554 | 5/20 | 0.34 |
| ▸ | CNR2 | P34972 | 3/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5782159 | 1.00 | CRHR1 (0.39) | CRHR1MAOBGABRA1GABRB2NPBWR1 | |
| SCHEMBL5782164 | 1.00 | CRHR1 (0.39) | CRHR1MAOBGABRA1GABRB2NPBWR1 | |
| SCHEMBL5800112 | 0.91 | CRHR1 (0.40) | CRHR1GABRA1CNR1CNR2 | |
| SCHEMBL6500617 | 0.91 | CRHR1 (0.40) | CRHR1GABRA1CNR1CNR2 | |
| SCHEMBL6500624 | 0.91 | CRHR1 (0.40) | CRHR1GABRA1CNR1CNR2 | |
| SCHEMBL5786221 | 0.90 | CRHR1 (0.44) | CRHR1GABRA1GABRB2NPBWR1MTNR1A | |
| SCHEMBL6503015 | 0.90 | CRHR1 (0.44) | CRHR1GABRA1GABRB2NPBWR1MTNR1A | |
| SCHEMBL6500940 | 0.90 | CRHR1 (0.41) | CRHR1MAOBGABRA1GABRB2NPBWR1 | |
| SCHEMBL5786218 | 0.90 | CRHR1 (0.44) | CRHR1GABRA1GABRB2NPBWR1MTNR1A | |
| SCHEMBL5783841 | 0.90 | CRHR1 (0.41) | CRHR1MAOBGABRA1GABRB2NPBWR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050020601-A1 | Novel pyrazinones as CRF1 receptor antagonists | PFIZER INC | 2005-01-27 | — | — | US | claimed |
| US-20050020601-A1 | Novel pyrazinones as CRF1 receptor antagonists | PFIZER INC | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020601-A1 | Novel pyrazinones as CRF1 receptor antagonists | CRHR1, CRHR2, CRH | CRHR1 1/4885MAOB 631/4885GABRA1 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.